Daichi Watanabe1, Hironori Fujii2, Nobuhisa Matsuhashi3, Hirotoshi Iihara1, Yunami Yamada1, Takuma Ishihara4, Takao Takahashi3,5, Kazuhiro Yoshida3, Akio Suzuki1. 1. Department of Pharmacy, Gifu University Hospital, Gifu, Japan. 2. Department of Pharmacy, Gifu University Hospital, Gifu, Japan h_fujii@gifu-u.ac.jp. 3. Department of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu, Japan. 4. Gifu University Hospital, Innovative and Clinical Research Promotion Center, Gifu University, Gifu, Japan. 5. Department of Frontier Science for Surgical Oncology, Gifu University Graduate School of Medicine, Gifu, Japan.
Abstract
BACKGROUND/AIM: The effect of renal dysfunction on the toxicity and efficacy of oxaliplatin remains unclear. We investigated the association between creatinine clearance (Ccr), a marker of renal function, and the toxicity and efficacy of oxaliplatin in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: Patients with mCRC who received oxaliplatin-based chemotherapy as first-line treatment were included in this study. Primary outcome was peripheral neuropathy (Grade ≥2), while secondary outcomes included neutropenia (Grade ≥3), thrombocytopenia (Grade ≥2) and overall survival (OS). RESULTS: A total of 145 patients with mCRC were eligible. Incidence rates of peripheral neuropathy (Grade ≥2), neutropenia (Grade ≥3) and thrombocytopenia (Grade ≥2) were 30.3%, 37.2% and 16.6%, respectively, and median OS was 29.1 months. Cox proportional hazards analysis indicated that there was no significant relationship between Ccr and any adverse event, or between Ccr and OS. CONCLUSION: Dose reduction of oxaliplatin based on Ccr is not recommended in patients with mCRC. Copyright
BACKGROUND/AIM: The effect of renal dysfunction on the toxicity and efficacy of oxaliplatin remains unclear. We investigated the association between creatinine clearance (Ccr), a marker of renal function, and the toxicity and efficacy of oxaliplatin in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: Patients with mCRC who received oxaliplatin-based chemotherapy as first-line treatment were included in this study. Primary outcome was peripheral neuropathy (Grade ≥2), while secondary outcomes included neutropenia (Grade ≥3), thrombocytopenia (Grade ≥2) and overall survival (OS). RESULTS: A total of 145 patients with mCRC were eligible. Incidence rates of peripheral neuropathy (Grade ≥2), neutropenia (Grade ≥3) and thrombocytopenia (Grade ≥2) were 30.3%, 37.2% and 16.6%, respectively, and median OS was 29.1 months. Cox proportional hazards analysis indicated that there was no significant relationship between Ccr and any adverse event, or between Ccr and OS. CONCLUSION: Dose reduction of oxaliplatin based on Ccr is not recommended in patients with mCRC. Copyright